Cosman F, de Beur SJ, LeBoff MS, Lewiecki EM, Tanner B, Randall S, et al. The National Osteoporosis Foundation. Clinician's Guide to Prevention and Treatment of Osteoporosis.
Osteoporos Int 2014; 25(10): 2359-81.
Cummings SR, Melton LJ. Epidemiology and outcomes of osteoporotic fractures. Lancet 2002 May 18; 359(9319): 1761-7.
European Medicines Agency concludes class review of bisphosphonates and atypical fractures. Rare atypical fractures of the femur: a class effect of bisphosphonates. 2011
http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2011/04/WC500105281.pd f Accessed 2015.6.2.
Fleisch H. Bisphosphonates in Bone Disease, Fourth Edition: From the Laboratory to the Patient.
Academic Press 2000; p. 34-55.
Fujiwara S, Kasagi F, Masunari N, Naito K, Suzuki G, Fukunaga M. Fracture prediction from bone mineral density in Japanese men and women. J Bone Miner Res 2003 Aug; 18(8): 1547-53.
Gehlbach S, Saag KG, Adachi JD, Hooven FH, Flahive J, Boonen S, et al. Previous fractures at multiple sites increase the risk for subsequent fractures: the Global Longitudinal Study of Osteoporosis in Women. J Bone Miner Res 2012; 27: 645-53.
Harrison RA, Siminoski K, Vethanayagam D, Majumdar SR. Osteoporosis-related kyphosis and impairments in pulmonary function: a systematic review. J Bone Miner Res 2007; 22: 447-57.
Kanis JA, McCloskey EV, Johansson H, Cooper C, Rizzoli R, Reginster JY. Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis and
Osteoarthritis (ESCEO) and the Committee of Scientific Advisors of the International Osteoporosis Foundation (IOF). European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 2013; 24(1): 23-57.
Kanis JA. WHO Study Group. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. Osteoporos Int 1994; 4: 368-81.
Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, et al.
Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007; 22(10): 1479-91.
Lenart BA, Lorich DG, Lane JM. Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N Engl J Med 2008; 358(12): 1304-6.
Leu CT, Luegmayr E, Freedman LP, Rodan GA, Reszka AA. Relative binding affinities of bisphosphonates for human bone and relationship to antiresorptive efficacy. Bone 2006; 38(5):
628-36.
Lewiecki EM, Miller PD. Renal safety of intravenous bisphosphonates in the treatment of osteoporosis. Expert Opin Drug Saf 2007; 6(6): 663-72.
Lindsay R, Silverman SL, Cooper C, Hanley DA, Barton I, Broy SB, et al. Risk of new vertebral fracture in the year following a fracture. JAMA 2001 Jan 17; 285(3): 320-3.
MacLean C, Newberry S, Maglione M, McMahon M, Ranganath V, Suttorp M, et al. Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med 2008 Feb 5; 148(3): 197-213.
Magaziner J, Lydick E, Hawkes W, Fox KM, Zimmerman SI, Epstein RS, Hebel JR, et al. Excess mortality attributable to hip fracture in white women aged 70 years and older. Am J Public Health 1997 Oct; 87(10): 1630-6.
Mukherjee S, Huang C, Guerra F, Wang K, Oldfield E. Thermodynamics of bisphosphonates binding to human bone: a two-site model. J Am Chem Soc 2009; 131(24): 8374-5.
NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy.
Osteoporosis prevention, diagnosis, and therapy. JAMA 2001; 285(6): 785-95.
Novartis Pharmaceuticals Corporation Briefing Document for the September 9, 2011 Joint Meeting of the Advisory Committee for Reproductive Health Drugs and the Drug Safety and Risk
Management Advisory Committee.
http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/drugsafetya ndriskmanagementadvisorycommittee/ucm270963.pdf Accessed 2015.4.22.
Prevention and management of osteoporosis. WHO Technical Report. World Health Organization 2003; 31-52.
Rogers MJ. New insights into the molecular mechanisms of action of bisphosphonates. Curr Pharm Des 2003; 9(32): 2643-58.
Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, et al. American
Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update. J Oral Maxillofac Surg 2014; 72(10): 1938-56.
Sakamoto K, Nakamura T, Hagino H, Endo N, Mori S, Muto Y, et al. Report on the Japanese Orthopaedic Association's 3-year project observing hip fractures at fixed-point hospitals. J Orthop Sci 2006; 11: 127-34.
Shane E, Burr D, Abrahamsen B, Adler RA, Brown TD, Cheung AM, et al. Atypical
subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American society for bone and mineral research. J Bone Miner Res 2014; 29(1): 1-23.
Siris ES, Selby PL, Saag KG, Borgström F, Herings RM, Silverman SL. Impact of osteoporosis treatment adherence on fracture rates in North America and Europe. Am J Med 2009; 122(2 Suppl):
S3-13.
Suzuki Y, Nawata H, Soen S, Fujiwara S, Nakayama H, Tanaka I, et al. Guidelines on the
management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research: 2014 update. J Bone Miner Metab 2014 Jul; 32(4): 337-50.
Tanvetyanon T, Stiff PJ. Management of the adverse effects associated with intravenous bisphosphonates. Ann Oncol 2006; 17(6): 897-907.
Thom T, Haase N, Rosamond W, Howard VJ, Rumsfeld J, Manolio T, et al. Heart disease and stroke statistics--2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2006; 113(6): e85-e151.
WHO. Guidelines for preclinical evaluation and clinical trials in osteoporosis. 1998.
Yamaguchi T, Sugimoto T, Yamauchi M, Matsumori Y, Tsutsumi M, Chihara K. Multiple vertebral fractures are associated with refractory reflux esophagitis in postmenopausal women. J Bone Miner Metab 2005; 23: 36-40.
折茂肇, 林𣳾史, 福永仁夫, 曽根照喜, 藤原佐枝子, 白木正孝, 他. 日本骨代謝学会骨粗鬆 症診断基準検討委員会. 原発性骨粗鬆症の診断基準（2000年度改訂版）. 日本骨代謝学会 誌 2001; 18(3): 76-82.
折茂肇 他. 骨粗鬆症の予防と治療ガイドライン作成委員会. 骨粗鬆症の予防と治療ガイ ドライン 2015年版. ライフサイエンス出版; 2015a. p. 4-5.
折茂肇 他. 骨粗鬆症の予防と治療ガイドライン作成委員会. 骨粗鬆症の予防と治療ガイ ドライン 2015年版. ライフサイエンス出版; 2015b. p. 78-85.
折茂肇 他. 骨粗鬆症の予防と治療ガイドライン作成委員会. 骨粗鬆症の予防と治療ガイ ドライン 2015年版. ライフサイエンス出版; 2015c. p. 96-97.